Table of Content
Announced on 22 September 2022 interest rates have now risen to 2.25% as the Bank of England tackles inflation.
"I’m thrilled and humbled to be joining the Focal Medical team as CEO," added Aldridge. Focal Medical’s lead product candidate uses its patented iontophoresis system for the local delivery of gemcitabine actively and directly to the tumor to treat advanced unresectable pancreatic cancer. In preclinical studies, 100% of pancreatic cancer tumors treated with gemcitabine using the system shrunk by an average of 40%, while tumors treated with intravenous gemcitabine grew an average of 140%i.
Current Appointments of Michael Aldridge
The average per patient cost of care is $280,433 in the first year of treatment and $312,077 in the second yeariii. Probably the most asked question within our industry over the last couple of years or so. It is true to say there is a greater need for more detailed financial information, which would now include 3 years audited accounts, up to date Management figures and both current and historic occupancy trends but providing this is forthcoming, a bank should look favourable at the deal. Mike Aldridge is a licensed real estate agent in DE & MD affiliated with Compass RE, a licensed real estate broker and abides by Equal Housing Opportunity laws.
To date, Focal Medical has raised over $20 million in equity and grant funding. Institutional investors include Khosla Ventures, Spectrum Financial and Piedmont Capital Partners. Price caps will certainly be needed and most welcomed by operators, with the overall message being to accelerate domestic energy supply to ease the burden. It is another area where future-proofing supply will be required but then again, the Care Home industry has always had future proofing challenges, which has never deterred astute buyers who continue to see the Care industry as unique and special. It is predicated that Care Home sales in the UK will continue at a decent pace, with demand outstripping supply for the higher end top quality businesses. With the market unlikely to slow due to recent rising interest rates, we believe the industry will remain active for the remainder of the year moving into 2023.
ALDRIDGE CARE HOMES - A NATIONWIDE CARE HOME AGENT
During 2022, it would appear there have been improvements in business trading positions throughout the UK, with better recovery prices being achieved since the pandemic. This is attributed to improved occupancy levels as Care Homes opened their doors again to new Residents. Also, the overcoming of uncertainty since the nationwide vaccination programme was implemented with the Autumn Booster Programme currently being implemented. Buying or selling a home can be a difficult process if you hire the wrong agent. Focal Medical’s pipeline expansion plans include products targeting other inoperable solid tumors and products utilizing its innovative technology to deliver gene therapy drugs. Other current news is, of course, rising interest rates, with indications that rates will continue to rise to curb inflation.
This may seem intimidating for buyers, but we need to remember that base rates are still at historically low levels in comparison to the 1980’s when rates reached between 10%-15%. This gradually decreased into single digits in the 1990’s and then with a global recession in 2008 all the way down to just 2%. Michael Aldridge currently holds the position of a Director in ALDRIDGE CARE HOMES LTD. He/she has been a Director of ALDRIDGE CARE HOMES LTD for 8 years. Following diagnosis, pancreatic cancer has a 5-year survival rate of only 11%ii. On diagnosis, only 15% of patients are eligible for surgical removal of the tumor.
QUALITY IS THE KEY
Focal Medical expects to file an IND with the FDA and initiate its first clinical trial in 2023. "I’m extremely proud of the progress we have made on our local drug delivery platform to bring us to this point, and I’m excited to be working with Michael to lead the growth and development of Focal Medical into our next chapter," commented Voiers. Focal Medical’s patented iontophoresis delivery system enables the internal, site-specific, active delivery of drugs directly and selectively to diseased target tissue or organs. The technology thus addresses the significant challenges and limitations of traditional systemic drug delivery approaches including toxicity and first-pass metabolism. Focal Medical is the new name of Advanced Chemotherapy Technologies. Focal Medical’s corporate rebranding is a function of a strategic shift towards broader product applications of its targeted drug delivery technology.
All material presented herein is intended for informational purposes only. Information is compiled from sources deemed reliable but is subject to errors, omissions, changes in price, condition, sale, or withdrawal without notice. Photos may be virtually staged or digitally enhanced and may not reflect actual property conditions. A track record of good levels of occupancy and resilience during recent years contribute to a stable and upward trajectory in EBITDAR and hence valuation levels. Quality Care Homes coming to the marketplace are acquired quickly with many offering single en-suite bedrooms, spacious accommodation or room to expand, with a good range of facilities and staff continuity with a good regulator record.
What are your thoughts on the trajectory of interest rates?
The Care Home industry over the last 10 years or so has seen both challenging and changing market conditions. With a seemingly reluctance of the banks to lend, supposedly reduced values being quoted to sellers and the ever increasing importance for a Home not to have any outstanding requirements, one would think the outlook was bleak – not the case. Throughout 2022 the interest for good quality Care Homes has remained robust with interest from new Care Home Buyers to the growing Independent Multisite Care Home Operator developing alongside the Corporate Operators. Michael Aldridge has been working at ALDRIDGE CARE HOMES LTDsince 18 June 2014, currently, he/she works on the position of a Director.
"As we prepare for our first clinical trial in pancreatic cancer and progress exciting new research in treating additional solid tumors and genomics medicine products, the future is very promising," commented Joseph M. DeSimone, Focal Medical Founder and Non-executive Chairman. The key word is now quality and if a business has the necessary criteria it should sell. This would include mainly single en-suite bedrooms, spacious accommodation with perhaps planning permission to increase the registration, a good range of quality amenities and facilities and a stable Staff base ideally qualified at NVQ level. It goes without saying that occupancy levels remain an important issue, with buyers and lenders expecting consistant numbers throughout the financial year. The appetite for good quality Care Homes has remained strong, with an every increasing influx of new buyers trying to enter the market – this coupled with experienced operators looking to add good quality businesses to their portfolio has helped maintain steady market conditions. Furthermore, evidence suggests that recent prices achieved have not fallen back as expected, with just a correction to what was conceived as previously inflated prices.
Focal Medical, Inc. is a privately held, biopharmaceutical company developing novel therapeutic products based on its innovative and patent protected local drug delivery technology platform. Focal Medical’s patented iontophoresis delivery system enables the internal, site-specific delivery of therapeutics actively, directly, and selectively to the diseased target tissue or organ. The technology thus addresses certain significant challenges and limitations of traditional systemic drug delivery approaches including toxicity and first-pass metabolism. Focal Medical’s lead product uses its patented iontophoresis system for the local delivery of gemcitabine actively and directly to the tumor to treat pancreatic cancer. Focal Medical is expanding its product focus into therapies for other solid tumors and gene therapy products, all utilizing its innovative energy-based drug delivery system.
No comments:
Post a Comment